289 related articles for article (PubMed ID: 34923391)
1. Intermediates of α-synuclein aggregation: Implications in Parkinson's disease pathogenesis.
Gadhe L; Sakunthala A; Mukherjee S; Gahlot N; Bera R; Sawner AS; Kadu P; Maji SK
Biophys Chem; 2022 Feb; 281():106736. PubMed ID: 34923391
[TBL] [Abstract][Full Text] [Related]
2. Phase separation and other forms of α-Synuclein self-assemblies.
Poudyal M; Sakunthala A; Mukherjee S; Gadhe L; Maji SK
Essays Biochem; 2022 Dec; 66(7):987-1000. PubMed ID: 36373662
[TBL] [Abstract][Full Text] [Related]
3. Liquid-liquid Phase Separation of α-Synuclein: A New Mechanistic Insight for α-Synuclein Aggregation Associated with Parkinson's Disease Pathogenesis.
Mukherjee S; Sakunthala A; Gadhe L; Poudyal M; Sawner AS; Kadu P; Maji SK
J Mol Biol; 2023 Jan; 435(1):167713. PubMed ID: 35787838
[TBL] [Abstract][Full Text] [Related]
4. A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of α-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in α-synuclein research.
Kumar ST; Donzelli S; Chiki A; Syed MMK; Lashuel HA
J Neurochem; 2020 Apr; 153(1):103-119. PubMed ID: 31925956
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
Mehra S; Sahay S; Maji SK
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
[TBL] [Abstract][Full Text] [Related]
6. The Role of α-Synuclein Oligomers in Parkinson's Disease.
Du XY; Xie XX; Liu RT
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33212758
[TBL] [Abstract][Full Text] [Related]
7. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology.
Kumar ST; Jagannath S; Francois C; Vanderstichele H; Stoops E; Lashuel HA
Neurobiol Dis; 2020 Dec; 146():105086. PubMed ID: 32971232
[TBL] [Abstract][Full Text] [Related]
8. Biasing the native α-synuclein conformational ensemble towards compact states abolishes aggregation and neurotoxicity.
Carija A; Pinheiro F; Pujols J; Brás IC; Lázaro DF; Santambrogio C; Grandori R; Outeiro TF; Navarro S; Ventura S
Redox Biol; 2019 Apr; 22():101135. PubMed ID: 30769283
[TBL] [Abstract][Full Text] [Related]
9. Research Progress of α-Synuclein Aggregation Inhibitors for Potential Parkinson's Disease Treatment.
Kalsoom I; Wang Y; Li B; Wen H
Mini Rev Med Chem; 2023; 23(20):1959-1974. PubMed ID: 37198991
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays.
Bellomo G; Paciotti S; Concha-Marambio L; Rizzo D; Wojdaƚa AL; Chiasserini D; Gatticchi L; Cerofolini L; Giuntini S; De Luca CMG; Ma Y; Farris CM; Pieraccini G; Bologna S; Filidei M; Ravera E; Lelli M; Moda F; Fragai M; Parnetti L; Luchinat C
Mol Neurodegener; 2023 Apr; 18(1):20. PubMed ID: 37005644
[TBL] [Abstract][Full Text] [Related]
11. The Hidden Cell-to-Cell Trail of α-Synuclein Aggregates.
Neupane S; De Cecco E; Aguzzi A
J Mol Biol; 2023 Jun; 435(12):167930. PubMed ID: 36566800
[TBL] [Abstract][Full Text] [Related]
12. Nitroalkylation of α-Synuclein by Nitro-Oleic Acid: Implications for Parkinson's Disease.
Chavarría C; Trostchansky A; Durán R; Rubbo H; Souza JM
Adv Exp Med Biol; 2019; 1127():169-179. PubMed ID: 31140178
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Critical Role of α-Synuclein in Parkinson's Disease and Other Synucleinopathies: from Tissue to Cellular and Molecular Levels.
Serratos IN; Hernández-Pérez E; Campos C; Aschner M; Santamaría A
Mol Neurobiol; 2022 Jan; 59(1):620-642. PubMed ID: 34750787
[TBL] [Abstract][Full Text] [Related]
14. The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease.
Miao Y; Meng H
Cell Commun Signal; 2024 Jan; 22(1):31. PubMed ID: 38216911
[TBL] [Abstract][Full Text] [Related]
15. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
Sahay S; Ghosh D; Singh PK; Maji SK
Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
[TBL] [Abstract][Full Text] [Related]
16. Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers.
Vaikath N; Sudhakaran I; Abdi I; Gupta V; Majbour N; Ghanem S; Abdesselem H; Vekrellis K; El-Agnaf O
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498957
[TBL] [Abstract][Full Text] [Related]
17. Aggregation and phase separation of α-synuclein in Parkinson's disease.
Han W; Wei M; Xu F; Niu Z
Chem Commun (Camb); 2024 Jun; 60(52):6581-6590. PubMed ID: 38808534
[TBL] [Abstract][Full Text] [Related]
18. Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation.
Chavarría C; Ivagnes R; Souza JM
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625583
[TBL] [Abstract][Full Text] [Related]
19. Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.
Moore K; Sengupta U; Puangmalai N; Bhatt N; Kayed R
Mol Neurobiol; 2023 May; 60(5):2691-2705. PubMed ID: 36707462
[TBL] [Abstract][Full Text] [Related]
20. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity.
Gupta V; Salim S; Hmila I; Vaikath NN; Sudhakaran IP; Ghanem SS; Majbour NK; Abdulla SA; Emara MM; Abdesselem HB; Lukacsovich T; Erskine D; El-Agnaf OMA
Sci Rep; 2020 May; 10(1):8137. PubMed ID: 32424162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
